STOCK TITAN

ANI Pharmaceuticals to Discuss Third Quarter 2023 Financial Results on November 8, 2023, at 8:30 a.m. ET

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
ANI Pharmaceuticals, Inc. will release its Q3 2023 financial results on November 8th. A conference call will be hosted by the President and CEO, and the Senior VP of Finance and CFO.
Positive
  • ANI Pharmaceuticals, Inc. will release its Q3 2023 financial results on November 8th.
Negative
  • None.

BAUDETTE, Minn., Oct. 25, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its third quarter 2023 financial results on Wednesday, November 8, 2023, prior to the market open.

Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:

Date Wednesday, November 8, 2023
   
Time 8:30 a.m. ET
   
Toll free (U.S.) 800-445-7795
   
Webcast (live and replay) www.anipharmaceuticals.com, under the “Investors” section
   

A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-6737 and entering access code 4379958.

About ANI

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com.

Investor Relations Contact:
Lisa M. Wilson, In-Site Communications, Inc.
212-452-2793
lwilson@insitecony.com

SOURCE: ANI Pharmaceuticals, Inc.


FAQ

When will ANI Pharmaceuticals release its Q3 2023 financial results?

ANI Pharmaceuticals will release its Q3 2023 financial results on November 8th.

Who will host the conference call to discuss the results?

The conference call will be hosted by the President and CEO, and the Senior VP of Finance and CFO.

Where can I access the webcast of the conference call?

The webcast can be accessed on www.anipharmaceuticals.com, under the 'Investors' section.

How long will the conference call replay be available?

The conference call replay will be available for two weeks.

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

ANIP Rankings

ANIP Latest News

ANIP Stock Data

1.40B
15.04M
11.2%
75.52%
0.94%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
BAUDETTE

About ANIP

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.